COMMENTARY

• Japan Moves to Break Plasma Product Capacity Crunch with Factory Aid
  October 6, 2026

• Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
  September 28, 2026

• Regional Formularies Gain Ground, Raising Stakes for Drug Makers, Wholesalers
  September 15, 2026

• As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
  September 7, 2026

• Pharma Faces Wage Challenge in 5% Era as Industry Sustainability at Stake
  September 3, 2026

• Beyond Dupixent: Next Wave of COPD Biologics Takes Shape
  August 25, 2026

• 9 Drugs Top 100 Billion Yen in FY2025 Japan Sales; Keytruda Retains Crown: Jiho Tally
  August 20, 2026

• Signs of Shift in Japan’s Drug Policy, but Cost Pressures Persist
  August 3, 2026

• Rare Cancer Case Raises New Questions about AAV Gene Therapy Safety
  July 27, 2026

• A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
  July 13, 2026

• DORA Use Could Expand as Japan Opens Door to “Sleep Disorders” Specialty
  July 6, 2026

• New Generic Listings Plunge, Industry Heads for a Shakeout
  July 1, 2026

• Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze
  June 16, 2026

• 20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag
  June 9, 2026

• Are Technical Discussions Enough for Japan’s CEA System?
  May 25, 2026

• Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises
  April 28, 2026

• Gene Therapies Expand into AMD, Raising Promise and Cost Concerns
  April 24, 2026

• Challenges in a Post-AG Era: Ensuring a Reliable Supply System
  April 6, 2026

• Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
  April 1, 2026

• A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste
  March 24, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »